www.luqmantrading.com • Professional Insights • Expert Commentary • Resource Center
www.luqmantrading.com

Before You Buy,vaccines

by DS Cassarino·2006·Cited by 20—The primary goal of peptide vaccinations with gp100 and tyrosinase isto activate melanoma-specific T cellsin order to prevent melanoma recurrence.

:is used as a cancer vaccine

A
Joan Simmons

analyzes '' product usability and accessibility with consistent information sharing on Discord and Reddit

Published on

Executive Summary

used as a cancer vaccine by DS Cassarino·2006·Cited by 20—The primary goal of peptide vaccinations with gp100 and tyrosinase isto activate melanoma-specific T cellsin order to prevent melanoma recurrence.

The glycoprotein 100 peptide vaccine represents a significant advancement in the field of cancer immunotherapy, specifically targeting melanoma. This peptide vaccine is designed to harness the power of the immune system to recognize and eliminate cancer cells expressing the glycoprotein 100 (gp100) antigen. Gp100 is a well-characterized melanocytic differentiation antigen, meaning it is found on melanocytes, the cells that produce pigment, and is often overexpressed in melanoma.

The development of the glycoprotein 100 peptide vaccine has focused on specific peptides derived from the gp100 protein. Prominent among these are Gp100:209-217(210M) and Gp100:280-288(288V). The Gp100:209-217(210M) variant is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 melanoma antigen, with a methionine substitution at position 210. This modification aims to enhance its immunogenicity. Similarly, the Gp100:280-288(288V) peptide vaccine comprises amino acids 280 through 288 of the gp100 antigen. These peptides are designed to bind to specific human leukocyte antigen (HLA) molecules, such as HLA-A2, making them recognizable by T cells.

Research into peptide vaccines has explored various strategies to maximize their efficacy. For instance, the gp100 (25-33) epitope, identified as a H-2Db restricted epitope, has been shown to activate specific CD8+ T cells capable of recognizing melanoma cells. The primary goal of vaccination with gp100 and similar antigens is to activate melanoma-specific T cells to help prevent melanoma recurrence.

Clinical trials have investigated the glycoprotein 100 peptide vaccine in various settings. A notable area of research involves combining the gp100 peptide vaccine with interleukin-2 (IL-2), an immune-activating agent. Studies, such as those by Schwartzentruber et al., hypothesized that this combination could improve outcomes in patients with advanced melanoma. These trials have demonstrated that vaccination with the gp100:209–217(210M) peptide can induce very high levels of circulating T cells capable of recognizing and killing melanoma cells. In some cases, the gp100 peptide vaccine was designed specifically to stimulate CD8+ T cells, and strategies involving anti-CTLA-4 antibodies were explored to augment these CD8+ T-cell responses.

The efficacy of peptide-based vaccines can be influenced by various factors. For example, research has indicated that the "hypo-responsiveness" of tumor cells induced by vaccination with gp100/IFA was associated with T cell apoptosis. Furthermore, the conjugation of cell-penetrating peptides to the gp100 (20–38) antigen peptide has been shown to increase immunogenicity in vivo significantly.

Beyond melanoma, the concept of peptide vaccines is being explored for other cancers. For instance, a multipeptide vaccine called ICT-107 comprises six peptides representing various tumor antigens. The development of personalized cancer vaccine approaches, which uses multiple peptides (amino acid sequences) to help the body's immune system recognize and attack cancer cells, is also a promising avenue.

While peptide vaccines offer a targeted approach, they have also been associated with potential side effects, such as hypercytokinemia. However, the ongoing research and development in peptide-based vaccines continue to refine their design and application, aiming to improve their safety and effectiveness in treating various diseases, including cancer. The Gp-100:209-217 is noted as the only peptide vaccine that has demonstrated a statistically significant clinical benefit in a phase III clinical trial for uveal melanoma. This highlights the potential of glycoprotein 100 (gp100) peptide vaccine as a therapeutic strategy.

Related Articles

Frequently Asked Questions

Here are the most common questions about .

by T Kumai·2022·Cited by 18—A phase III study combiningglycoprotein 100 (gp100) peptide vaccinewith IL-2 in advanced melanoma showed an improvement in the overall survival 
Definition of gp100:209-217(210M) peptide vaccine
gp100 peptide vaccine and interleukin-2 in patients - PubMed
We hypothesized that combining a melanomavaccinewith interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patients 

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More